Download
ORE517794.pdf 546,35KB
WeightNameValue
1000 Titel
  • The Use of Neuroprotective Agents in Treating Geographic Atrophy
1000 Autor/in
  1. Scholl, Hendrik |
  2. Boyer, David |
  3. Giani, Andrea |
  4. Chong, Victor |
1000 Verlag
  • S. Karger AG
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-21
1000 Erschienen in
1000 Quellenangabe
  • 64(6):888-902
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1159/000517794 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:p>Geographic atrophy (GA) secondary to age-related macular degeneration accounts for close to one-quarter of cases of legal blindness in the USA and the UK. Despite this notable disease burden, the pathophysiology of GA is complex and not fully understood, and there is currently no approved treatment to prevent or slow its progression. GA is heterogeneous in its appearance and extent, and underlying associated traits such as drusen and complement factor polymorphisms vary between patients and by ethnicity, posing a challenge for treatment development. The root cause of vision loss in GA is photoreceptor death; therefore, protecting photoreceptors from damage and delaying their degeneration are key to successful GA treatment. There are multiple neuroprotective pathways that may contribute to protecting photoreceptors from damage, and compounds that target these pathways include antioxidants, neurotrophic factors, and catalases. However, the efficacy of previously trialled neuroprotective therapies in GA, such as brimonidine, tandospirone, and NT-501, has been inconsistent; this may be due to their target of action, method of delivery, and/or suboptimal duration of action. Neurotrophic factors, or molecules involved in neuroprotective signalling cascades, may be ideal agents for further investigation for the treatment of GA. Future neuroprotective strategies in GA must focus on the development of agents with a long duration of action that can combat the progression of chronic damage in GA to provide clinically meaningful benefits for patients. </jats:p>
1000 Sacherschließung
lokal Atrophy [MeSH]
lokal Geographic Atrophy/drug therapy [MeSH]
lokal Neurotrophic factors
lokal Age-related macular degeneration
lokal Humans [MeSH]
lokal Review Article
lokal Retina
lokal Retina [MeSH]
lokal Geographic atrophy
lokal Neuroprotective Agents/therapeutic use [MeSH]
lokal Neuroprotection
lokal Nerve Growth Factors [MeSH]
lokal Macular Degeneration [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-7312-0316|https://frl.publisso.de/adhoc/uri/Qm95ZXIsIERhdmlk|https://frl.publisso.de/adhoc/uri/R2lhbmksIEFuZHJlYQ==|https://frl.publisso.de/adhoc/uri/Q2hvbmcsIFZpY3Rvcg==
1000 Hinweis
  • DeepGreen-ID: 75e36f246f6243b38f591c659d872f45 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6440029.rdf
1000 Erstellt am 2023-01-30T09:18:17.967+0100
1000 Erstellt von 322
1000 beschreibt frl:6440029
1000 Zuletzt bearbeitet 2024-10-07T09:16:55.325+0200
1000 Objekt bearb. Mon Oct 07 09:16:55 CEST 2024
1000 Vgl. frl:6440029
1000 Oai Id
  1. oai:frl.publisso.de:frl:6440029 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source